Home » Stocks » FNCH

Finch Therapeutics Group, Inc. (FNCH)

Stock Price: $14.86 USD 0.57 (3.99%)
Updated Jun 17, 2021 1:52 PM EDT - Market open
Market Cap 677.63M
Revenue (ttm) 9.48M
Net Income (ttm) n/a
Shares Out 14.03M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $14.86
Previous Close $14.29
Change ($) 0.57
Change (%) 3.99%
Day's Open 14.12
Day's Range 14.00 - 14.86
Day's Volume 21,914
52-Week Range 11.56 - 22.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...

2 weeks ago - GlobeNewsWire

SOMERVILLE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or the “Company”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First ...

1 month ago - GlobeNewsWire

SOMERVILLE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human...

1 month ago - GlobeNewsWire

SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

1 month ago - GlobeNewsWire

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

Other stocks mentioned: AFCG, CNTB, GANX, JWEL, NAPA, OLO, SNCY ...
2 months ago - Benzinga

SOMERVILLE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Hum...

2 months ago - GlobeNewsWire

Finch Therapeutics Group, a Phase 3-ready biotech developing microbiome therapeutics, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

Finch Therapeutics Group, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About FNCH

Finch Therapeutics Group is a clinical-stage microbiome therapeutics company leveraging our Human-First Discovery platform to develop a novel class of orally administered biological drugs. The microbiome consists of trillions of microbes that live symbiotically in and on every human and are essential to our health. When key microbes are lost, the resulting dysbiosis can increase susceptibility to immune disorders, infections, neurological conditions, cancer and other serious diseases. We are developing novel therapeutics designed to deliver mis... [Read more...]

Industry
Biotechnology
IPO Date
Mar 19, 2021
CEO
Mark Smith, Ph.D.
Employees
165
Stock Exchange
NASDAQ
Ticker Symbol
FNCH
Full Company Profile

Financial Performance

In 2020, FNCH's revenue was $7.72 million, a decrease of -23.98% compared to the previous year's $10.15 million. Losses were -$39.34 million, 89.6% more than in 2019.

Financial Statements